



R. Zander

# **Fluid Management**

Second expanded (corrected) edition

**Bibliographic information published by the Deutsche Nationalbibliothek**

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available in the Internet at <http://dnb.d-nb.de>.

My special thanks go to Kerstin Faude (B.Braun Melsungen AG) for her insightful help and support in writing this booklet – second edition (RZ).

Univ.-Prof. Dr. med. R. Zander  
Physioklin  
Am Fort Gonsenheim 51a  
55122 Mainz, Germany

Phone +49 (0) 61 31 - 97 190 97

Fax +49 (0) 61 31 - 97 191 97

E-Mail: [zander@physioklin.de](mailto:zander@physioklin.de)

Infoportal: [www.physioklin.de](http://www.physioklin.de)

Former name of institution: *Institut für Physiologie und Pathophysiologie*  
University of Mainz, Germany

Copyright Shaker Verlag 2023

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers.

ISBN 978-3-8440-8984-4

DOI 10.2370/9783844089844

Shaker Verlag GmbH • Am Langen Graben 15a • 52353 Düren

Phone: 0049/2421/99011-0 • Telefax: 0049/2421/99011-9

Internet: [www.shaker.de](http://www.shaker.de) • e-mail: [info@shaker.de](mailto:info@shaker.de)

---

R. Zander

# **Fluid Management**

Second expanded (corrected) edition

---

---

## Table of Contents

1. Why a Booklet?	7
1.1. Why a Second Edition?	7
2. Volume Replacement Vs. Fluid Replacement: Two Aspects of Fluid Management	9
3. Why Balanced Solutions?	11
4. What Should Go Into a Balanced Solution?	12
4.1. Cations	13
4.2. Chloride	13
4.3. Bicarbonate and Dilutional Acidosis	15
4.4. Metabolizable Anions	18
4.4.1. Acetate	19
4.4.2. Lactate	24
4.4.2.1. Lactate Metabolism	24
4.4.2.2. Does Lactate Increase Oxygen Consumption?	26
4.4.2.3. Lactate Clearance	26
4.4.2.4. Lactate and Mortality	28
4.4.2.5. Ringer's Lactate and Lactate Assay	29
4.4.2.6. Specific Issues with Lactate	30
4.4.3. Advantages of Acetate Over Lactate	30
4.4.4. Malate	31
4.4.5. Gluconate	31
4.4.6. Citrate	31
5. Isotonic	32
5.1. Osmolarity (mosmol/L) and Osmolality (mosmol/kg H <sub>2</sub> O)	32
5.2. Physiological Normal Value of Osmolality	35
5.3. <i>In vivo</i> Vs. <i>in vitro</i> Osmolality	35
5.4. Hypotonic IV Fluids and Intracranial Pressure (ICP)	36
5.5. The Pathophysiology of Hyperosmolality	40

---

---

<b>6. Effects of Infusion Fluids on a Patient's Acid-Base Balance</b>	<b>42</b>
6.1. Labeling	42
6.2. What Does a BEpot of 0 mmol/L Mean for the Patient?	43
6.3. Base Excess and Mortality in Multiple Trauma Patients	44
6.4. BE Clearance and Mortality in Trauma Patients	46
6.5. Does Alcohol Interfere with BE Measurements?	46
6.6. Why Is Metabolic Acidosis a Problem?	46
6.7. Base Excess and Clotting	47
6.7.1. BE and Measurement of Coagulation Status	50
6.7.2. Alleged Effects of Colloids on Coagulation	52
6.7.3. Coagulation and Ionized Calcium	52
<b>7. Differentiation Between Colloid Volume Replacement and Crystalloid Fluid Replacement</b>	<b>54</b>
7.1. The Clinical Physiology of Major Fluid Compartments	54
7.2. Would-Be Volume Replacement with Crystalloids	56
7.3. Fluid Overload – Pulmonary Edema	62
7.4. Fluid Overload – Increase in Body Weight	62
7.5. Fluid Overload – Compartment Syndrome	64
7.6. Parameters Used for Control of Volume Replacement Therapy	65
7.6.1. Central Venous Pressure (CVP)	66
7.6.2. CVP Dynamics (CVP Titration)	68
7.6.3. Dynamic Parameters Downstream of the Heart	71
7.7. Is There a Particular Level of Volume Loss That Should Trigger a Switch From Stop Gap Crystalloid Fluid Replacement to Genuine Volume Replacement with Colloids?	71

---

---

<b>8. Differentiation Between Volume Replacement Therapy and Blood Therapy</b>	<b>73</b>
8.1. Volume Replacement Therapy with Natural Colloids (HA)	73
8.2. Volume Replacement Therapy with Synthetic Colloids (DEX, GEL, HES)	74
8.2.1. Specific Indication for Use: Erythrocyte Protection	76
8.2.2. Specific Indication for Use: Hyperoncotic Solutions	77
8.2.3. Specific Limitation – Renal Function	77
8.3. Hemotherapy Using Packed Red Cells or Whole Blood	78
8.4. Infusion- and Hemotherapy in Massive Hemorrhage	84
<b>9. Special Considerations in Pediatric Patients</b>	<b>87</b>
<b>10. Summary &amp; Conclusion</b>	<b>90</b>
<b>References</b>	<b>93</b>
<b>Acronyms &amp; Abbreviations</b>	<b>123</b>

---